Clinical outcomes of percutaneous microwave ablation for pulmonary oligometastases from hepatocellular carcinoma: a retrospective, multicenter study

Abstract Background Pulmonary oligometastases are common in hepatocellular carcinoma (HCC), however, the existing therapeutic options have several limitations. This study aimed to assess the safety and efficacy of microwave ablation (MWA) in the treatment of HCC-originating pulmonary oligometastases...

Full description

Bibliographic Details
Main Authors: Gang Wang, Zhigang Wei, Feihang Wang, Xiaoying Han, Haipeng Jia, Danyang Zhao, Chunhai Li, Lingxiao Liu, Xia Yang, Xin Ye
Format: Article
Language:English
Published: BMC 2024-03-01
Series:Cancer Imaging
Subjects:
Online Access:https://doi.org/10.1186/s40644-024-00679-7
_version_ 1797273400898486272
author Gang Wang
Zhigang Wei
Feihang Wang
Xiaoying Han
Haipeng Jia
Danyang Zhao
Chunhai Li
Lingxiao Liu
Xia Yang
Xin Ye
author_facet Gang Wang
Zhigang Wei
Feihang Wang
Xiaoying Han
Haipeng Jia
Danyang Zhao
Chunhai Li
Lingxiao Liu
Xia Yang
Xin Ye
author_sort Gang Wang
collection DOAJ
description Abstract Background Pulmonary oligometastases are common in hepatocellular carcinoma (HCC), however, the existing therapeutic options have several limitations. This study aimed to assess the safety and efficacy of microwave ablation (MWA) in the treatment of HCC-originating pulmonary oligometastases. Methods A total of 83 patients, comprising 73 males and 10 females with a median age of 57 years, who had pulmonary oligometastases from HCC, underwent MWA treatment at four different medical institutions. Inclusion criteria for patients involved having primary HCC under control and having less than three oligometastases with a maximum diameter of ≤ 5 cm in the unilateral lung or less than five oligometastases with a maximum diameter of ≤ 3 cm in the bilateral lung. A total of 147 tumors were treated with MWA over 116 sessions. The primary endpoints assessed included technical success, treatment efficacy, and local progression rate, while secondary endpoints encompassed complications, clinical outcomes, overall survival (OS), local progression-free survival (LPFS), and prognostic factors. Results The technical success rate for MWA was 100% (116/116 sessions), and the treatment efficacy rate was 82.3% (121/147 tumors). Six months after MWA, the local progression rate was 23.1% (18/147 tumors). Complications were observed in 10.3% (major) and 47.4% (minor) of the 116 sessions, with no cases of ablation-related deaths. The median follow-up period was 21.6 months (range: 5.7–87.8 months). Median OS was 22.0 months, and the 1-, 2-, and 3-year OS rates were 82.6%, 44.5%, and 25.2%, respectively. Median LPFS was 8.5 months. Multivariate Cox regression analysis identified α-fetoprotein (AFP) levels during initial diagnosis and the number of oligometastases as potential independent prognostic factors for OS (p = 0.017 and 0.045, respectively). Conclusion Percutaneous MWA is a safe and effective treatment modality for pulmonary oligometastases originating from HCC.
first_indexed 2024-03-07T14:43:49Z
format Article
id doaj.art-92b5032885254402842478af855f01e3
institution Directory Open Access Journal
issn 1470-7330
language English
last_indexed 2024-03-07T14:43:49Z
publishDate 2024-03-01
publisher BMC
record_format Article
series Cancer Imaging
spelling doaj.art-92b5032885254402842478af855f01e32024-03-05T20:08:19ZengBMCCancer Imaging1470-73302024-03-012411910.1186/s40644-024-00679-7Clinical outcomes of percutaneous microwave ablation for pulmonary oligometastases from hepatocellular carcinoma: a retrospective, multicenter studyGang Wang0Zhigang Wei1Feihang Wang2Xiaoying Han3Haipeng Jia4Danyang Zhao5Chunhai Li6Lingxiao Liu7Xia Yang8Xin Ye9Department of Oncology, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer InstituteDepartment of Oncology, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer InstituteDepartment of Interventional Radiology, Zhongshan Hospital, Fudan UniversityDepartment of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityDepartment of Radiology, Qilu Hospital of Shandong UniversityDepartment of Interventional Radiology, Zhongshan Hospital, Fudan UniversityDepartment of Radiology, Qilu Hospital of Shandong UniversityDepartment of Interventional Radiology, Zhongshan Hospital, Fudan UniversityDepartment of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical UniversityDepartment of Oncology, Shandong Key Laboratory of Rheumatic Disease and Translational Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer InstituteAbstract Background Pulmonary oligometastases are common in hepatocellular carcinoma (HCC), however, the existing therapeutic options have several limitations. This study aimed to assess the safety and efficacy of microwave ablation (MWA) in the treatment of HCC-originating pulmonary oligometastases. Methods A total of 83 patients, comprising 73 males and 10 females with a median age of 57 years, who had pulmonary oligometastases from HCC, underwent MWA treatment at four different medical institutions. Inclusion criteria for patients involved having primary HCC under control and having less than three oligometastases with a maximum diameter of ≤ 5 cm in the unilateral lung or less than five oligometastases with a maximum diameter of ≤ 3 cm in the bilateral lung. A total of 147 tumors were treated with MWA over 116 sessions. The primary endpoints assessed included technical success, treatment efficacy, and local progression rate, while secondary endpoints encompassed complications, clinical outcomes, overall survival (OS), local progression-free survival (LPFS), and prognostic factors. Results The technical success rate for MWA was 100% (116/116 sessions), and the treatment efficacy rate was 82.3% (121/147 tumors). Six months after MWA, the local progression rate was 23.1% (18/147 tumors). Complications were observed in 10.3% (major) and 47.4% (minor) of the 116 sessions, with no cases of ablation-related deaths. The median follow-up period was 21.6 months (range: 5.7–87.8 months). Median OS was 22.0 months, and the 1-, 2-, and 3-year OS rates were 82.6%, 44.5%, and 25.2%, respectively. Median LPFS was 8.5 months. Multivariate Cox regression analysis identified α-fetoprotein (AFP) levels during initial diagnosis and the number of oligometastases as potential independent prognostic factors for OS (p = 0.017 and 0.045, respectively). Conclusion Percutaneous MWA is a safe and effective treatment modality for pulmonary oligometastases originating from HCC.https://doi.org/10.1186/s40644-024-00679-7Pulmonary oligometastasesHepatocellular carcinomaMicrowave ablationMulticenter study
spellingShingle Gang Wang
Zhigang Wei
Feihang Wang
Xiaoying Han
Haipeng Jia
Danyang Zhao
Chunhai Li
Lingxiao Liu
Xia Yang
Xin Ye
Clinical outcomes of percutaneous microwave ablation for pulmonary oligometastases from hepatocellular carcinoma: a retrospective, multicenter study
Cancer Imaging
Pulmonary oligometastases
Hepatocellular carcinoma
Microwave ablation
Multicenter study
title Clinical outcomes of percutaneous microwave ablation for pulmonary oligometastases from hepatocellular carcinoma: a retrospective, multicenter study
title_full Clinical outcomes of percutaneous microwave ablation for pulmonary oligometastases from hepatocellular carcinoma: a retrospective, multicenter study
title_fullStr Clinical outcomes of percutaneous microwave ablation for pulmonary oligometastases from hepatocellular carcinoma: a retrospective, multicenter study
title_full_unstemmed Clinical outcomes of percutaneous microwave ablation for pulmonary oligometastases from hepatocellular carcinoma: a retrospective, multicenter study
title_short Clinical outcomes of percutaneous microwave ablation for pulmonary oligometastases from hepatocellular carcinoma: a retrospective, multicenter study
title_sort clinical outcomes of percutaneous microwave ablation for pulmonary oligometastases from hepatocellular carcinoma a retrospective multicenter study
topic Pulmonary oligometastases
Hepatocellular carcinoma
Microwave ablation
Multicenter study
url https://doi.org/10.1186/s40644-024-00679-7
work_keys_str_mv AT gangwang clinicaloutcomesofpercutaneousmicrowaveablationforpulmonaryoligometastasesfromhepatocellularcarcinomaaretrospectivemulticenterstudy
AT zhigangwei clinicaloutcomesofpercutaneousmicrowaveablationforpulmonaryoligometastasesfromhepatocellularcarcinomaaretrospectivemulticenterstudy
AT feihangwang clinicaloutcomesofpercutaneousmicrowaveablationforpulmonaryoligometastasesfromhepatocellularcarcinomaaretrospectivemulticenterstudy
AT xiaoyinghan clinicaloutcomesofpercutaneousmicrowaveablationforpulmonaryoligometastasesfromhepatocellularcarcinomaaretrospectivemulticenterstudy
AT haipengjia clinicaloutcomesofpercutaneousmicrowaveablationforpulmonaryoligometastasesfromhepatocellularcarcinomaaretrospectivemulticenterstudy
AT danyangzhao clinicaloutcomesofpercutaneousmicrowaveablationforpulmonaryoligometastasesfromhepatocellularcarcinomaaretrospectivemulticenterstudy
AT chunhaili clinicaloutcomesofpercutaneousmicrowaveablationforpulmonaryoligometastasesfromhepatocellularcarcinomaaretrospectivemulticenterstudy
AT lingxiaoliu clinicaloutcomesofpercutaneousmicrowaveablationforpulmonaryoligometastasesfromhepatocellularcarcinomaaretrospectivemulticenterstudy
AT xiayang clinicaloutcomesofpercutaneousmicrowaveablationforpulmonaryoligometastasesfromhepatocellularcarcinomaaretrospectivemulticenterstudy
AT xinye clinicaloutcomesofpercutaneousmicrowaveablationforpulmonaryoligometastasesfromhepatocellularcarcinomaaretrospectivemulticenterstudy